Looking for:
Grupo opcao 3 2011 download cd |
Configurar um dispositivo para RAID - Grupo opcao 3 2011 download cd
Effects of limiting fluid intake on clinical and laboratory outcomes in patients with heart failure. Results of a meta-analysis of randomized controlled trials. Outros estudos de menor porte mostram resultados inconsistentes. A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure SALT-HF. Liberal versus restricted fluid prescription in stabilised patients with chronic heart failure: result of a randomised cross-over study of the effects on health-related quality of life, physical capacity, thirst and morbidity.
Scand Cardiovasc J. Prog Cardiovasc Dis. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. Improvement in dilated cardiomyopathyafter bariatric surgery. Obesity and the risk of heartfailure. Wasting as independent riskfactor for mortality in chronic heart failure.
The obesity paradox: fact orfiction? Am J Cardiol ;98 7 Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure the GISSI-HF trial : a randomised, double-blind, placebo-controlled trial.
Coenzyme Q10 for heart failure. Cochrane Database Syst Rev. Vitamin D status and outcomes in heart failure patients. A randomized controlled trial of high dose vitamin D3 in patients with heartfailure. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial VitD-CHF trial.
Vitamin D supplementation in the treatment of chronic heart failure: a metaanalysis of randomized controlled trials. Influenza vaccination and risk for hospitalization in patients with heart failure: a self-controlled case series study. Cardioprotective effect of influenza and pneumococcal vaccinationin patients with cardiovascular diseases. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention.
Effects of aerobic exercise training on autonomic balance, brain natriuretic peptide, and quality of life evaluation in dilated cardiomyopathy patients. Comparing exercise training modalities in heart failure: A systematic review and meta-analysis. Randomized, controlled trialof long-term moderate exercise training in chronic heart failure: effectson functional capacity, quality of life, and clinical outcome.
Exercise training meta-analysis of trials in patients with chronicheart failure. Psychosocial factors, exercise adherence, and outcomes in heart failure patients: insights from heart failure: a controlled trial investigating outcomes of exercise training HF-ACTION. Exercise-based rehabilitation for heart failure. Safety and efficacy of aerobic exercise training associated to non-invasive ventilation in patients with acute heart failure.
Impact of exercise training on peak oxygen uptake and its determinants in heart failure with preserved ejection fraction. Card Fail Rev. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction.
Effect of exercise on diastolic functionl in heart failure patients: a systematic reviewand meta-analysis. Low intensity is better than high intensity exercise training in chronic heart failure patients concerning pulmonary ventilation, brain natriuretic peptide, and quality of life evaluation: A prospective randomized study. High-intensity interval trainingin patients with heart failure with reduced ejection fraction.
Exercise-based rehabilitation for heart failure: systematic review and meta-analysis Open Heart. Addition of inspiratory muscle training to aerobic training imp roves cardiorespiratoryresponses to exercise in patients with heart failure and inspiratory muscleweakness.
Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflammatory Bowel Diseases ;12 5 Circulation ; 14 Sexual function of patients with heart failure: facts and numbers. Cardiovascular risk, drugs and erectile function-a systematic analysis. Int J ClinPract. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association.
Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
Contraception in patients with heart failure. Circulation ; 11 A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. Effects of enalapril on mortality in severe congestive heart failure. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. Acute Infarction Ramipril Efficacy. Valsartan, captopril, orboth in myocardial infarction complicated by heart failure, left ventriculardysfunction, or both.
Effects of candesartan inpatients with chronic heart failure and reduced left-ventricular systolicfunction intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
O uso concomitante de IECA implica aumento discreto, mas significativo de efeitos adversos. Safety and tolerability ofangiotensin-converting enzyme inhibitor versus the combination ofangiotensin-converting enzyme inhibitor and angiotensin receptorblocker in patients with left ventricular dysfunction: a systematic reviewand meta-analysis of randomized controlled trials.
Effects of candesartan inpatients with chronic heart failure and reduced left-ventricular systolicfunction taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Effect of carvedilol on survival in severe chronic heart failure. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure SENIORS.
Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators. Eplerenone in patients with systolic heart failure and mild symptoms. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
Vasopeptidase inhibition and angio-oedema. Br J Clin Pharmacol. Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. Ivabradine in the treatment of systolic heart failure: a systematic review and meta-analysis. World J Cardiol. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receivinga? Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
Entretanto, ivabradina, em estudos preliminares, reduziu a FC na FA. Emerging role of ivabradine for rate control in atrial fibrillation. Ther Adv Cardiovasc Dis.
The effect of digoxin on mortality and morbidity in patients with heart failure. Does digitalis work in chronic heart failure? The end of a year-old controversy. Cardiovasc Drugs Ther. Este ensaio randomizou 6. Digitalis for treatment of heart failure in patients in sinus rhythm. Digoxin for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
PLoS One. Digoxin and mortality in patients with atrial fibrillation. Diuretic strategies in patients with acute decompensated heart failure. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. Relation of loop diuretic dose to mortality in advanced heart failure.
Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration Cooperative Study. Combined oral hydralazine-nitrate therapy in left ventricular failure hemodynamic equivalency to sodium nitroprusside. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure trials. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Usefulness of isosorbide dinitrate and hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure.
O algoritmo representado na figura 7. Figura 7. Phenotypic spectrum of heart failure with preserved ejection fracion. Heart failure with preserved ejection fraction: controversies challenges and future directions. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Spironolactone for heart failure with preserved ejection fraction. Drug treatment effects in outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis Heart. Irbesartan in patients with heart failure and preserved ejection fraction. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, Irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction.
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction.
Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial.
Role of biomarkers in cardiac structurephenotyping in heart failure with preservedejection fraction: critical appraisal andpractical use. Phenotype-specific treatment of heart failure with preserved ejection fraction - A multiorgan roadmap. Cardiac resynchronization in chronic heart failure. Cardiac-resynchronization therapy with orwithout an implantable defibrillator in advanced chronic heart failure. The effect of cardiac resynchronization onmorbidity and mortality in heart failure.
Cardiac-resynchronization therapy for theprevention of heart-failure events. Cardiac-resynchronization therapy formild-to-moderate heart failure. Survival with cardiac-resynchronizationtherapy in mild heart failure. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care?
Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failurehospitalisation in patients with non-left bundlebranch block QRS morphology: meta-analysis of randomised controlled trials.
Biventricular pacing for atrioventricular block and systolic dysfunction. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial.
Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis.
Heart Rhythm. Cardiac resynchronization therapy in patients with atrial fibrillation. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous rightventricular pacing. Comparative long-term outcomes after cardiac resynchronization therapy in right ventricular paced patients versus native wide left bundle branch block patients.
Mode of death in chronic heart failure. A request and propostion for more accurate classification. Reducing the risk of sudden death in heart failure with beta-blokers. Sudden cardiac death: the role of medical therapy.
Declining risk of sudden cardiac death in heart failure. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Eng J Med. Meta-analysis of the implantable defibrillator secondary prevention trials.
Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. Amiodarone or an implantable cardioverter-defibrilator for congestive heart failure. Neste estudo, foram randomizados 2.
Cabe ressaltar que alguns estudos tiveram resultados negativos. Lessons learned from neutral ICD trials. Prophylatic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.
Defibrillator implantation in patients with nonischemic systolic heart failure. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomayopathy: a meta-analysis. Implantable cardioverter- defibrillators for primary prevention of mortality in patients with nonischemic cardiomayopathy: a meta-analysis of randomized controlled trials. J Cardiovasc Electrophysiol. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of patients in 11 trials.
Primary prevention implantable cardioverter defibrillators in patients with noischemic cardiomayopathy: a meta-analysis of randomised cotrolled trials. BMJ Open. Implantable cardioverter- defibrillators for primary prevention in patients with ischemic and nonischemic cardiomayopathy: a systematic review and meta-analysis. Ann Intern Med. Predictors of serious arrhythmic events in patients with nonischemic heart failure. J Interv Card Electrophysiol.
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. Does intensity of rate-control influence outcome in atrial fibrillation? Lenient versus strict rate control in patients with atrial fibrillation.
Should beta-blockers be used in patients with heart failure and atrial fibrillation? Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Rhythm control versus rate control for atrial fibrillation and heart failure.
Spontaneous conversion and maintenance of sinusrhythmby amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy CHF-STAT. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction.
Heart Lung Circ. Catheter ablation for atrial fibrillation with heart failure. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey in atrial fibrillation. EurHeart J. Non-vitamin K antagonist oral anticoagulants NOACs in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. Dabigatran versus warfarin in patients with mechanical heart valves. Relationship between burden of premature ventricular complexes and left ventricular function. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study.
Post-mortem ICD interrogation in mode of death classification. Sudden cardiac death in heart failure patients with preserved ejection fraction. Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction: secondary analysis of the Sudden Cardiac Death in Heart FailureTrial. Impact of aldosterone antagonists on sudden cardiac death prevention in heart failure and post-myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials.
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocksfrom implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. Executive summary: heart disease and stroke statistics update: a report from the American Heart Association.
Ischemic left ventricle systolic dysfunction: an evidence-based approach in diagnostic tools and therapeutics. Rev Assoc Med Bras Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: A systematic angiography approach.
Arch Cardiovasc Dis. Coronary-artery bypass surgery in patients with left ventricular dysfunction. Ten-Year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH Trial Surgical Treatment for Ischemic Heart Failure.
Can functional testing for ischemia andviability guide revascularization? Use of coronary computed tomographic angiography to guide management of patients with coronary disease. Factors associated with false-negative cardiovascular magnetic resonance perfusion studies: a clinical evaluation of magnetic resonance imaging in coronary artery disease CE-MARC substudy.
J Magn Reson Imaging. Chronic heart failure in the United States: a manifestation of coronary artery disease. Comparison of surgical andmedical group survival in patients with left main coronary artery disease: long-term CASS experience. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy.
Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. The progression from hypertension to congestive heart failure. Erratum in: J Am Coll Cardiol. A randomized trial of intensive versus standard blood-pressure control. Effects of blood pressure lowering on outcome incidence in hypertension: 7.
Effects of more vs. J Hypertens. Blood pressure lowering for prevention of cardiovascular disease and death: a? Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Erratum in: JAMA.
Vasodilation by urapidil in the treatment of chronic congestive heart failure in additionto angiotensin-converting enzyme inhibitors is not beneficial: results of aplacebo-controlled, double-blind study. Clinicalimportance of the renin-angiotensin system in chronic heart failure: double blindcomparison of captopril and prazosin. The association between blood pressure and mortality in patients with heart failure.
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. Leaflet remodelling in functional mitral valve regurgitation: characteristics, determinants, and relation to regurgitation severity. Eur Heart J Cardiovasc Imaging. Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction.
Impact of mitral valve annuloplasty combined withrevascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol ;49 22 Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. Br Heart J. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Early and late effects of cardiac resynchronization therapy on exercise-induced mitral regurgitation: relationship with left ventricular dyssynchrony, remodelling and cardiopulmonary performance. Short- and medium-term effects of combined mitral valve surgery and coronary artery bypass grafting versus coronary artery bypass grafting alone for patients with moderate ischemic mitral regurgitation: a meta-analysis.
J Cardiothorac Vasc Anesth. Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients. Effectiveness of MitraClip therapy in patients with refractory heart failure. J Interv Cardiol. Safety and efficacy of MitraClip tm therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions TRAMI registry. Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular aortic stenosis.
Clinical profile and natural historyof nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg. Transcatheter versus surgicalaortic-valve replacement in high-risk patients.
N Engl J Med ; 23 Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.
N Engl J Med ; 1 CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. Low-gradient aortic stenosis. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.
Erratum in: J Card Fail ;4 4 Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65, patients. Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure.
Rosuvastatin in older patients with systolic heart failure. Effect of rosuvastatin in patients with chronic heart failure the GISSI-HF trial : a randomised, double-blind, placebo-controlled trial.
Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: a sub-analysis of GISSI-HF trial.
Pulm Pharmacol Ther. Statins and left ventricular function. Curr Pharm Des. Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship.
Insulin resistance and risk of congestive heart failure. European Guidelines on cardiovascular disease prevention in clinical practice version Prevalence, incidence and clinical impact of cachexia: facts and numbers. Update J Cachexia Sarcopenia Muscle. Cardiac cachexia: a systematic overview. Pharmacol Ther. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology. Diabetes, impaired fasting glucose, and heart failure: it's not all about the sugar.
The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Long-term effects of intensive glucose lowering on cardiovascular outcomes.
Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U. General Practice Research Database. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. Correction: the association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials.
Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.
Am J Cardiovasc Drugs. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Cardiovasc Diabetol. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Tanto o hipertireoidismo quanto hipotireoidismo podem causar IC. Isso justifica o rastreamento de tireoideopatias em todos pacientes com IC. Thyroid replacement therapy and heart failure. Pacientes em uso de amiodarona devem ter o TSH dosado regularmente a cada 6 meses.
Nos casos de hipertireoidismo, o tratamento inicial com metimazol 5 a 10 mg ao dia pode ser a escolha, e aconselha-se consulta posterior com endocrinologista para avaliar tratamento definitivo. Thyroid disease and the heart. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Renal dysfunction and heart failure: things are seldom what they seem. Microalbuminuria in nondiabetic and nonhypertensive systolic heart failure patients.
Congest Heart Fail. High prevalence of microalbuminuria in chronic heart failure patients. Acute kidney injury and chronic kidney disease as interconnected syndromes. The kidney in heart failure: an update. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial.
Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Is spironolactone safe for dialysis patients?
Nephrol Dial Transplant. Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and hour blood pressure profile. Eur J Clin Pharmacol. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
J Heart Lung Transplant. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Respir Med. Nestes casos, deve-se priorizar o uso dos BB seletivos. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia.
Erectile dysfunction in heart failure patients. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function.
Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Elevated C-reactive protein in patients with obstructive sleep apnea. Sleep apnoea in heart failure: to treat or not to treat? Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart failure.
Heart failure and sleep apnea. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. Non-Invasive Ventilation in patients with heart failure: a systematic review and meta-analysis. CPAP for prevention of cardiovascular events in obstructive sleep apnea. Meta-analysis of cardiovascular outcomes with continuous positive airway pressure therapy in patients with obstructive sleep apnea.
Epidemiology of cardio-oncology. Cardio-oncology: the clinical overlap of cancer and heart disease. Switzerland: Springer; A historical perspective of anthracycline cardiotoxicity. Incidence of cancer in patients with chronic heart failure: a long-term follow-up study.
Cardiovascular complications of cancer therapy. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. O ecocardiograma tridimensional tem melhor desempenho que o bidimensional, mas apresenta menor disponibilidade.
Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.
J Clin Oncol. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic ressonance imaging. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity.
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. Depression increases the risk of mortality in patients with heart failure: a meta-analysis. J Psychosom Res. Heart failure and depression. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.
Cognitive behavior therapy for depression and self-care in heart failure patients: a randomized clinical trial. The effect of antidepressant medications in the management of heart failure on outcomes: mortality, cardiovascular function and depression - a systematic review. Int J Psychiatry Clin Pract. Mortality indicators among chronic Chagas patients living in an endemic area.
The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era. International Cardiovascular Forum Journal. Rev Esp Cardiol. Predictors of all-cause mortality in chronic Chagas heart disease in the current era of heart failure therapy. Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy. Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy.
Prognosis of patients with chronic systolic heart failure: Chagas disease versus systemic arterial hypertension. Prognostic impact of Chagas disease in patients awaiting heart transplantation. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Randomized trial of benznidazole for chronic Chagas cardiomyopathy.
A randomized trial of the effects of exercise training in Chagas cardiomyopathy. Effects of B-Blockers on outcome of patients with Chagas cardiomyopathy with chronic heart failure. B-Blocker therapy and mortality of patients with Chagas cardiomyopathy. Aldosterone antagonism in na inflammatory state: evidence for myocardial protection. J Renin Angiotensin Aldosterone Syst. Digoxin serum levels in patients with Chagas cardiomyopathy and heart failure.
Rev Soc Bras Med Trop. Prevalence and risk factors of embolic cerebrovascular events associated with Chagas heart disease. Glob Heart. Mode of death on Chagas heart disease: comparison with other etiologies. Plos Negl Trop Dis. Clinical predictors of inducible sustained ventricular tachycardia during Electrophysiologic study in patients with chronic Chagas heart disease.
Int J Cardiol Heart Vasc. Functional behavior of patients with conventional pacemakers undergoing cardiac resynchronization. Cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy: long-term follow up.
Rev Bras Cir Cardiovasc. Implantable cardioverter-defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy. Long-term follow-up of patients with chronic Chagas disease and implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. The paradox of survival results after heart transplantation caused by Trypanosoma cruzi. Effects of a mycophenolate mofetil-based immunosuppressive regimen in Chagas heart transplant recipients.
Pregnancy in patients with heart disease: experience with 1, cases. Clin Cardiol. Heart failure in pregnant woman: a concern across the pregnancy continuum. Asymptomatic left ventricular dysfunction in puerperal women: an echocardiographic-based study. Peripartum cardiomyopathy. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol.
Neste caso, prefere-se o uso de heparina de baixo peso molecular ou anticoagulantes orais. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study.
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Left ventricular noncompactioncardiomyopathy: cardiac, neuromuscular, and genetic factors.
Noncompaction cardiomyopathy: The role of advanced multimodality imaging techniques in diagnosis and assessment. Isolated noncompaction of the myocardium in adults. Mayo Clin Proc. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Left ventricularnon-compaction: prevalence in congenital heart disease.
Isolated noncompaction of left ventricular myocardium: a study of eight cases. Limitations in the diagnosis of noncompaction cardiomyopathy by echocardiography. Varieddistributions of late gadolinium enhancement found among patients meetingcardiovascular magnetic resonance criteria for isolated left ventricularnon-compaction.
Prevalence of Takotsubo cardiomyopathy in the United States. Int JCardiol. Pathophysiology of Takotsubo syndrome. Apical ballooning syndrome Tako-Tsubo or stress cardiomyopathy : a mimic of acute myocardialinfarction. Use of levosimendan forcardiogenic shock in a patient with the apical ballooning syndrome. Clinical management of Takotsubocardiomyopathy. Circ J. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction.
Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction.
Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Fussing over the middle child: heart failure with mid-range ejection fraction. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Heart failure with mid-range ejection fraction: causes and consequences. Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Palliative care: the World Health Organization's global perspective. J Pain Symptom Manage. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology.
Use of risk models to predict death in the next year among individual ambulatory patients with heart failure. Managing the symptoms of advancing heart failure. End-of-life care in patients with heart failure. Conselho Federal de Medicina. Rio de Janeiro: Ed. Revinter; Decisions at the end of life: have we come of age? BMC Medicine. O direito de morrer com dignidade. Tudo deve ser feito, mesmo que cause sofrimento atroz ao paciente.
Ato deliberado de provocar a morte sem sofrimento do paciente por fins misericordiosos. Cardiovascular health in Brazil.
The economic burden of heart conditions in Brazil. Value in Health. Evolution of heart failure-related hospital admissions and mortality-rates. Int J Cardiovasc Sci. Congestive heart failure. In: Weintraub W. Cardiovascular healthcare economics. New Jersey: Humana Press; Long term health care consumption and cost expenditure in systolic heart failure. Eur J Intern Med. Cost and cost-effectiveness studies in heart failure research. Cost-effectiveness of heart failure therapies. Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.
Cost effectiveness of eplerenone in patients with chronic heart failure. Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure.
Value Health. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. Cost-effectiveness of sacubitril-valsartan in patients who have heart failure with reduced ejection fraction. Cost-effectiveness of a nurse facilitated, cognitive behavioural self-management programme compared with usual care using a CBT manual alone for patients with heart failure: secondary analysis of data from the SEMAPHFOR trial.
Trial Investigators. Cost-effectiveness of home versus clinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort - The WHICH? Cost-effectiveness of multidisciplinary management program and exercise training program in heart failure. Cost-effectiveness of supervised exercise therapy in heart failure patients. Value Health ;4 5 Suppl 1 : S J Telemed Telecare.
Economic impact assessment from the use of a mobile app for the self-management of heart diseases by patients with heart failure in a Spanish region. J Med Syst. Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure INH study.
Baran, James Bourne Captain Hook 8. Brit Awards. Consultado em 12 de janeiro de Independent News and Media. Mercury Records. Consultado em 28 de setembro de Bauer Media Group. Consultado em 13 de novembro de The Official Charts Company. Digital Spy. Music Week. Consultado em 12 de setembro de Irish Recorded Music Association.
Consultado em 14 de novembro de Mail Online Daily Mail. Evento ocorre em On Set with Pixie Lott entrevista. Box Television. Consultado em 16 de janeiro de Consultado em 26 de novembro de Consultado em 12 de agosto de MTV Brasil.
Independent Television. Channel 4. The Dome. Capital FM. Universal Music Malaysia. Sabah Publishing House. Consultado em 1 de junho de Herald Media Inc. The Star Online Star Publications. Channel NewsAsia MediaCorp.
❿ ❿
No comments:
Post a Comment